In a closely watched Brazilian pharmaceutical patent dispute, the Court of Justice of São Paulo dismissed the opposing motions for clarification filed by both parties in Case No. 1138602-76.2022.8.26.0100/50001, closing proceedings on July 26, 2024. The case centered on patent BRPI0212726B1, a Brazilian patent covering composite lactam compounds, their derivatives, and related pharmaceutical compositions. Brazilian generics and cosmetics manufacturer Cosmed had brought a declaratory judgment action against Bristol-Myers Squibb Holdings Ireland Unlimited Company, seeking a judicial determination regarding the scope or validity of BMS’s pharmaceutical patent rights.

This case is significant for IP practitioners and pharmaceutical companies operating in Brazil’s competitive generic drug market. The dismissal of both clarification motions without substantive resolution on the merits underscores the procedural complexity of declaratory judgment actions in Brazilian state courts and highlights the strategic interplay between patent holders and generic manufacturers seeking freedom-to-operate in the Brazilian pharmaceutical sector. In-house counsel, litigation attorneys, and R&D teams should closely examine how Brazilian courts handle pharmaceutical patent declaratory actions.

Aperçu du dossier

Les parties

Le brevet en cause

Patent BRPI0212726B1 covers composite lactam compounds — a class of cyclic amide molecules widely used as active pharmaceutical ingredients — including their derivatives and pharmaceutical compositions incorporating them. Lactam-based compounds are foundational to a broad range of therapeutic drugs, including antibiotics and cardiovascular or oncology agents. The patent’s claims extend to the use of these compositions, meaning third parties manufacturing or commercializing such compounds in Brazil without authorization could face infringement exposure.

• • BRPI0212726B1

Chronologie du litige et historique de la procédure

This case was filed in the Court of Justice of São Paulo (Tribunal de Justiça do Estado de São Paulo — TJSP), Brazil’s state-level appellate court system. The filing before a state court rather than federal IP tribunal is notable: in Brazil, declaratory judgment actions concerning patent validity typically fall within the jurisdiction of the federal courts (Justiça Federal), while contractual and commercial disputes may reach state courts. The case classification as ‘other’ trial level and its routing through São Paulo’s state judiciary suggests the proceeding may have involved ancillary commercial or contractual claims alongside the core patent declaratory relief sought by Cosmed.

The case closed on July 26, 2024, with the basis of termination recorded as ‘Appeal Dismissed.’ The presiding judge rejected both parties’ opposing motions for clarification (embargos de declaração), a procedural mechanism under Brazilian civil procedure used to resolve ambiguities or omissions in prior decisions. The rejection of clarification motions from both sides signals that the court considered the prior ruling sufficiently clear and complete, effectively foreclosing further appellate review at this procedural stage without rendering a new substantive determination on the patent’s validity or scope.

Le verdict et l'analyse juridique

Résultat

The Court of Justice of São Paulo rejected both opposing motions for clarification filed by Cosmed and Bristol-Myers Squibb, closing the case on July 26, 2024. No damages award or injunctive relief determination was made at this stage, as the ruling was procedural in nature — declining to revisit or clarify the substance of the prior decision. The appeal was formally dismissed, leaving the underlying declaratory judgment outcome intact without further elaboration from the court.

Analyse des causes du verdict

The verdict cause of Declaratory Judgment, resolved through dismissal of clarification motions, reflects the following key legal grounds and procedural findings:

• Both Cosmed and Bristol-Myers Squibb filed embargos de declaração (motions for clarification) against the prior decision, indicating both parties found aspects of the ruling ambiguous or insufficiently reasoned.
• The court expressly rejected both motions, finding no omission, contradiction, or obscurity in the prior decision sufficient to warrant clarification under Brazilian civil procedure (CPC Art. 1,022).
• The basis of termination as ‘Appeal Dismissed’ confirms that the procedural avenue pursued by both parties was exhausted at this level without a new substantive ruling on patent BRPI0212726B1.
• The declaratory judgment framework was invoked by Cosmed to seek a judicial determination on BMS’s patent rights — a common strategy for generic manufacturers facing potential infringement claims in Brazil.

Signification juridique

1. 1. This case illustrates the procedural hurdles generic manufacturers face when pursuing declaratory judgment actions against multinational pharmaceutical patent holders in Brazilian state courts, where jurisdictional questions may complicate substantive review.
2. 2. The rejection of clarification motions from both parties without fresh substantive analysis means the underlying patent BRPI0212726B1 retains its legal status in Brazil, preserving BMS’s enforcement position until a competent court rules on validity or scope.
3. 3. The case signals that Brazilian courts will not easily reopen concluded proceedings via clarification motions when the prior decision is deemed sufficiently clear, limiting the utility of embargos de declaração as a de facto appellate strategy in patent disputes.

Points stratégiques à retenir

Pour les avocats spécialisés en brevets :

• When advising generic manufacturers in Brazil, ensure declaratory judgment actions targeting multinational pharma patents are filed in the correct federal jurisdiction (Justiça Federal / INPI-linked proceedings) to avoid procedural dismissals at the state court level.
• Motions for clarification (embargos de declaração) should be reserved for genuine ambiguities in the ruling and not used as a secondary appellate mechanism; courts consistently reject motions that effectively seek reconsideration of settled points.
• Monitor the validity status of BRPI0212726B1 through INPI administrative channels alongside litigation, as administrative nullity proceedings before Brazil’s patent office may offer a parallel and more effective route to challenging the patent.
• Document any jurisdictional arguments at the outset of declaratory judgment actions in Brazil, particularly where state and federal court competences overlap in pharmaceutical patent matters, to preserve appellate options.

Pour les professionnels de la propriété intellectuelle :

• In-house IP teams at pharmaceutical companies operating in Brazil should map their key patent assets against pending declaratory judgment actions filed by generic manufacturers, as Brazilian state courts may reach different outcomes than federal IP tribunals.
• BMS’s successful defense of this procedural challenge preserves the enforceability of BRPI0212726B1 in Brazil; competitor companies should update their FTO analyses to account for the continued validity of this lactam compound patent.

Pour les équipes de R&D :

• R&D teams developing lactam-based pharmaceutical compositions for the Brazilian market should conduct thorough freedom-to-operate assessments against BRPI0212726B1 before advancing compounds to clinical or commercial stages.
• Consider design-around strategies focused on structural modifications to lactam scaffolds or alternative pharmaceutical formulations that fall outside the granted claims of BRPI0212726B1 as interpreted by Brazilian courts.